Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jul 10, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how two topical lotions—clindamycin and triamcinolone—can help prevent skin-related side effects caused by a treatment called Tumor Treating Fields (TTFields) in people with glioblastoma, a type of brain cancer. TTFields is a therapy that delivers electrical fields to disrupt cancer cell growth, but it can sometimes cause skin irritation. The goal of this study is to see if these lotions can make the treatment more comfortable for patients.

To participate in the trial, you should be at least 18 years old and have either newly diagnosed or recurrent glioblastoma, with plans to start TTFields treatment soon. You should also be able to apply the lotions yourself or have someone help you. However, certain conditions, like having an allergy to the lotions or existing skin problems on your scalp, may prevent you from joining. If you choose to participate, you will be monitored for any skin reactions while using the lotions alongside your TTFields treatment. This study is currently looking for participants, and your involvement could help improve care for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Diagnosis of newly diagnosed or recurrent GBM with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution
• • Able to self-administer topical interventions or has available another person who can apply the topical agents
• • Treatment with TTF should be initiated within 7 days of planned initiation on this trial.
• Exclusion Criteria:
• • Known history of allergy to any ingredient of the study agents
• • Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.
• • Use of concurrent topical therapy to the scalp for another dermatologic condition
• • Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment
• • Use of greater than 4 mg dexamethasone a day within 14 days of enrollment
• • Malignant glioma
• • Pregnant Women